ECEESPE2025 ePoster Presentations Growth Axis and Syndromes (132 abstracts)
SEENEZ trial: growth prediction model from mid-puberty to near-adult height in adolescents with idiopathic isolated growth hormone deficiency treated with growth hormone
Joeri Vliegenthart 1 , Maria de Ridder 2 , Jan Maarten Wit 3 , Ardine Reedijk 4 , Raoul Oude Engberink 2 , Boudewijn Bakker 5 , Annemieke Boot 6 , Christiaan de Bruin 3 , Martijn Finken 7 , Josine van der Heyden 8 , Anita Hokken Koelega 4 , Hetty van der Kamp 9 , Edgar van Mil 10 , Theo C.J Sas 1 , Nina Schott 11 , Petra van Setten 12 , Saartje Straetemans 13 , Vera van Tellingen 14 , Bob Touwslager 15 , Paul van Trotsenburg 7 , Paul Voorhoeve 16 , Erica van den Akker 1 & Daniëlle van der Kaay 1
1Erasmus MC Sophia Children’s Hospital, Rotterdam, Netherlands; 2Erasmus University Medical Centre, Rotterdam, Netherlands; 3Willem-Alexander Children’s Hospital, Leiden University Medical Centre, Leiden, Netherlands; 4Dutch Growth Research Foundation, Rotterdam, Netherlands; 5Reinier de Graaf Gasthuis, Delft, Netherlands; 6Beatrix Children’s Hospital, University Medical Centre Groningen, Groningen, Netherlands; 7Emma Children’s Hospital, Amsterdam University Medical Center, Amsterdam, Netherlands; 8Franciscus Gasthuis & Vlietland, Rotterdam, Netherlands; 9Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, Netherlands; 10Jeroen Bosch Hospital, ‘s-Hertogenbosch, Netherlands; 11Zuyderland Hospital, Heerlen, Netherlands; 12Amalia Children’s Hospital, Radboud University Medical Center, Nijmegen, Netherlands; 13Maastricht University Medical Center, Maastricht, Netherlands; 14Catharina Hospital, Eindhoven, Netherlands; 15St. Antonius Hospital, Nieuwegein, Netherlands; 16Canisius Wilhelmina Hospital, Nijmegen, Netherlands
JOINT14
Background: Recombinant human growth hormone (rhGH) treatment in children with idiopathic isolated growth hormone deficiency (IIGHD) typically results in catch-up growth for several years followed by a period of normal growth. The efficacy of rhGH for late pubertal height gain in adolescents with IIGHD remains unclear.
Aims: This study aimed to develop and validate a model predicting height gain (cm) from mid-puberty to near adult height (NAH; height velocity <2cm/y) in IIGHD patients who were GH sufficient upon retesting at NAH.
Methods: For model development, data from the Dutch National Registry of Growth Hormone Treatment in Children were used, focusing on 151 patients with IIGHD (98 males, 53 females) who received rhGH treatment until NAH. Participants diagnosed with IIGHD (GH peak at diagnosis 1.7-10 µg/L) received rhGH treatment for a minimum of 2.5 years. GH peak was >10 µg/L upon retesting at NAH, with treatment discontinued for at least 1 month. Mid-puberty was defined for males as Tanner stage G3-G4, testicular volume >12 ml, and bone age (BA) 13-16 years, and for females as Tanner stage B3-B4 and BA 11-14 years. If no GH retest had been conducted, we used IGF-I >0 SDS after cessation of therapy and the pediatric endocrinologist’s judgment to determine GH sufficiency. Validation was done in 33 males and 7 females from the prospective SEENEZ trial.
Results: In the model, final predictors at mid-puberty included age, BA, Tanner stage, and target height (TH) SDS minus height SDS at mid-puberty. Adjusted for overoptimism the equation for males was: 82.07 - 1.41 * Tanner stage 4 or 5 - 2.55 * age – 2.36 * BA + 2.33 * (TH SDS - height SDS). R2 was 48%, residual SD was 4.16 cm. For females: 39.85 - 0.57 * age – 1.72 * BA. R2 was 18%, residual SD was 3.64 cm. Validation analysis showed a mean (SD) difference of 1.48cm (2.36) for males and 3.57cm (2.66) for females between predicted and attained NAH.
Conclusions: This study developed a prediction model for height gain in adolescents with IIGHD during rhGH treatment in the final stages of puberty. For females, explained variance was insufficient to reliably predict height gain. For GH sufficient males, the model can be used to assess efficacy of continuing or discontinuing rhGH treatment at mid-puberty in prospective studies and to facilitate shared decision-making regarding treatment continuation at mid-puberty.
Volume 110
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more